KX2-391 is primarily studied for its potential applications in cancer treatment. It functions as a Src kinase inhibitor, targeting and inhibiting the activity of Src family kinases, which are often implicated in the growth, survival, and metastasis of cancer cells. This makes it a promising candidate for therapeutic use in various types of cancers, including breast, prostate, and colon cancers. Researchers are exploring its efficacy in preclinical and clinical settings to determine its potential as a targeted therapy. Additionally, KX2-391 is being investigated for its role in reducing tumor growth and preventing cancer cell proliferation, offering a potential avenue for developing more effective cancer treatments.